AbCellera Biologics Inc. (ABCL) Revenue by Segment & Business Profile
Research Fees was 96.3% of AbCellera Biologics Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABCLAbCellera Biologics Inc.Follow ABCL — free
—
Price chart with a free account
- Market cap
- 3.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
What the company does
AbCellera Biologics Inc. is a drug manufacturers - general company in the healthcare sector. In its SEC filings it reports 2 business lines: Research Fees (96%), Licensing And Royalty Revenue (4%). Trailing twelve-month revenue: $66.2 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Biologics / biotech major
Revenue by geography
fiscal year 2025 · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| Canada | 64M | 85.2% | +144.3% |
| United States | 11M | 14.8% | +311.1% |
AbCellera Biologics Inc. — questions
- What does AbCellera Biologics Inc. do?
- AbCellera Biologics Inc. is a drug manufacturers - general company in the healthcare sector. In its SEC filings it reports 2 business lines: Research Fees (96%), Licensing And Royalty Revenue (4%). Trailing twelve-month revenue: $66.2 million as of 2026-06-30.
- How does AbCellera Biologics Inc. make money?
- By the lines it reports in its SEC filings: Research Fees 96.3%, Licensing And Royalty Revenue 3.7% of revenue.
Every figure on this page comes from AbCellera Biologics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.